Eli Lilly reported tirzepatide sales of $10.1 billion in Q3, making the molecule the world’s best‑selling drug and prompting the company to raise revenue forecasts. The drug’s branded uses (Mounjaro for diabetes and Zepbound for obesity) are driving rapid top‑line growth and market share in metabolic disease. To meet growing demand and broaden its oral portfolio, Lilly is investing $1.2 billion to build a Puerto Rico facility to produce orforglipron, an oral GLP‑1 candidate. The factory investment reflects a push to secure scalable manufacturing for both injectable and oral GLP‑1 formats amid intense competition. The convergence of massive sales and new capital allocation toward domestic manufacturing underscores how blockbuster obesity care is reshaping Big Pharma industrial planning and distribution strategies.